trelanserin
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2006 (NCT00300339)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serotonin 1b (5-HT1b) receptorANTAGONIST
HTR1B antagonist
- Serotonin 2a (5-HT2a) receptorANTAGONIST
HTR2A antagonist
Chemistry & pharmacology
Loading structure…
SMILES
NC(=O)Cn1c(=O)cc(CCN2CCN(c3nccc4sccc34)CC2)c2ccc(F)cc21- Mol. weight
- 465.55 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3183740 ↗
Also known as
- 7-fluoro-2-oxo-4-(2-(4-(thieno(3,2-c)pyridin-4-yl)piperazin-1-yl)ethyl)-1,2-dihydroquinoline-1-acetamide
- sl650472
- sl 65.0472
- sl65.0472
- sl65.0472
- trelanserin
- trelanserin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00300339 | Phase 2 | Feb 1, 2006 | Sanofi |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 1 | 1 | 1 | 2006 |
1 organizations
Page 1 / 1